keyword
MENU ▼
Read by QxMD icon Read
search

Pcnsl

keyword
https://www.readbyqxmd.com/read/28521029/soluble-taci-and-soluble-bcma-as-biomarkers-in-primary-central-nervous-system-lymphoma
#1
Franziska S Thaler, Sarah A Laurent, Marion Huber, Matthias Mulazzani, Martin Dreyling, Uwe Ködel, Tania Kümpfel, Andreas Straube, Edgar Meinl, Louisa von Baumgarten
Background: B-cell survival is regulated through interactions of B-cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). We evaluated the diagnostic potential of soluble TACI (sTACI) and soluble BCMA (sBCMA) in cerebrospinal fluid (CSF) and serum as biomarkers in primary CNS lymphoma (PCNSL). Methods: CSF (n=176) and serum samples (n=105) from patients with clinically or radiologically suspected PCNSL as well as from control patients were collected prospectively...
May 17, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28514747/diagnostic-value-of-using-18f-fdg-pet-and-pet-ct-in-immunocompetent-patients-with-primary-central-nervous-system-lymphoma-a-systematic-review-and-meta-analysis
#2
Yaru Zou, Jianjing Tong, Haiyan Leng, Jingwei Jiang, Meng Pan, Zi Chen
BACKGROUND: 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and PET/CT have become two of the most powerful tools for malignant lymphoma exploration, but their diagnostic role in primary central nervous system lymphoma (PCNSL) is still disputed. The purpose of our study is to identify the usefulness of 18F-FDG PET and PET/CT for detecting PCNSL. RESULTS: A total of 129 patients, obtained from eight eligible studies, were included for this systematic review and meta-analysis...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28508176/the-prognostic-role-of-cd68-and-foxp3-expression-in-patients-with-primary-central-nervous-system-lymphoma
#3
Hyunsoo Cho, Se Hoon Kim, Soo-Jeong Kim, Jong Hee Chang, Woo Ick Yang, Chang-Ok Suh, June-Won Cheong, Yu Ri Kim, Jung Yeon Lee, Ji Eun Jang, Yundeok Kim, Yoo Hong Min, Jin Seok Kim
The prognostic role of CD68 and FoxP3 in primary central nervous system lymphoma (PCNSL) has not been evaluated. Thus, we examined the prognostic significance of CD68 and FoxP3 expression in tumor samples of 76 newly diagnosed immunocompetent PCNSL patients. All patients were treated initially with high-dose methotrexate (HD-MTX)-based chemotherapy, and 16 (21.1%) patients received upfront autologous stem cell transplantation (ASCT) consolidation. High expression of CD68 (>55 cells/high-power field) or FoxP3 (>15 cells/high-power field) was observed in 10 patients, respectively...
May 15, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28507804/hla-dependent-immune-escape-mechanisms-in-b-cell-lymphomas-implications-for-immune-checkpoint-inhibitor-therapy
#4
Marcel Nijland, Rianne N Veenstra, Lydia Visser, Chuanhui Xu, Kushi Kushekhar, Gustaaf W van Imhoff, Philip M Kluin, Anke van den Berg, Arjan Diepstra
Antigen presentation by tumor cells in the context of Human Leukocyte Antigen (HLA) is generally considered to be a prerequisite for effective immune checkpoint inhibitor therapy. We evaluated cell surface HLA class I, HLA class II and cytoplasmic HLA-DM staining by immunohistochemistry (IHC) in 389 classical Hodgkin lymphomas (cHL), 22 nodular lymphocyte predominant Hodgkin lymphomas (NLPHL), 137 diffuse large B-cell lymphomas (DLBCL), 39 primary central nervous system lymphomas (PCNSL) and 19 testicular lymphomas...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28489744/diagnostic-accuracy-of-spect-pet-and-mrs-for-primary-central-nervous-system-lymphoma-in-hiv-patients-a-systematic-review-and-meta-analysis
#5
Mo Yang, James Sun, Harrison X Bai, Yongguang Tao, Xiangqi Tang, Lisa J States, Zishu Zhang, Jianhua Zhou, Michael D Farwell, Paul Zhang, Bo Xiao, Li Yang
BACKGROUND: We performed a systematic review and meta-analysis to assess the roles of SPECT, PET, and MRS in distinguishing primary central nervous system lymphoma (PCNSL) from other focal brain lesions (FBLs) in human immunodeficiency virus (HIV)-infected patients. METHODS: PubMed, Scopus, and Medline were systematically searched for eligible studies from 1980 to 2016. Two authors extracted characteristics of patients and their lesions using predefined criteria...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28476199/primary-central-nervous-system-lymphoma-as-a-neurosurgical-problem
#6
REVIEW
Dariusz Szczepanek, Ewa Wąsik-Szczepanek, Filip Stoma, Bożena Sokołowska, Tomasz Trojanowski
Primary central nervous system lymphoma (PCNSL) comprises around 3-5% of primary central nervous system (CNS) tumours and around 1% of all non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common histological type. High effectiveness of chemo- and radiotherapy for PCNSL regrettably does not eliminate significant risks of recurrence for CNS tumours. That results in higher interest in other treatment options, including surgical procedures. PCNSL remains in the scope of interest for many specialists and neurosurgeons seem to play a more important role...
April 19, 2017: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/28467782/methotrexate-cytarabine-dexamethasone-combination-chemotherapy-with-or-without-rituximab-in-patients-with-primary-central-nervous-system-lymphoma
#7
Xuefei Sun, Jing Liu, Yaming Wang, Xueyan Bai, Yuedan Chen, Jun Qian, Hong Zhu, Fusheng Liu, Xiaoguang Qiu, Shengjun Sun, Nan Ji, Yuanbo Liu
PURPOSE: High-dose methotrexate based chemotherapy is the standard treatment for patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The role of rituximab is controversial because of its large size, which limits its penetration of the blood-brain barrier. In this study, we investigated the efficacy and tolerability of adding rituximab to methotrexate-cytarabine-dexamethasone combination therapy (RMAD regimen). RESULTS: The patients treated with RMAD had a complete remission rate of 66...
April 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28466877/haematological-cancer-nivolumab-is-effective-in-pcnsl-and-ptl
#8
Peter Sidaway
No abstract text is available yet for this article.
May 3, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28436974/high-dose-thiotepa-based-chemotherapy-with-autologous-stem-cell-support-in-elderly-patients-with-primary-central-nervous-system-lymphoma-a-european-retrospective-study
#9
E Schorb, C P Fox, K Fritsch, L Isbell, A Neubauer, A Tzalavras, R Witherall, S Choquet, O Kuittinen, D De-Silva, K Cwynarski, C Houillier, K Hoang-Xuan, V Touitou, N Cassoux, J-P Marolleau, J Tamburini, R Houot, V Delwail, G Illerhaus, C Soussain, B Kasenda
In this retrospective multicentre study, we investigated the outcomes of elderly primary central nervous system lymphoma (PCNSL) patients (⩾65 years) who underwent high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) at 11 centres between 2003 and 2016. End points included remission, progression-free survival (PFS), overall survival (OS) and treatment-related mortality. We identified 52 patients (median age 68.5 years, median Karnofsky Performance Status before HDT-ASCT 80%) who all underwent thiotepa-based HDT-ASCT...
April 24, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28434043/early-whole-brain-radiotherapy-in-primary-cns-lymphoma-negative-impact-on-quality-of-life-in-the-randomized-g-pcnsl-sg1-trial
#10
Ulrich Herrlinger, Niklas Schäfer, Rolf Fimmers, Frank Griesinger, Michael Rauch, Heinz Kirchen, Patrick Roth, Martin Glas, Michael Bamberg, Peter Martus, Eckhard Thiel, Agnieszka Korfel, Michael Weller
PURPOSE: In the randomized G-PCNSL-SG-1 trial, the addition of whole brain radiotherapy (45 Gy) to high-dose methotrexate (HD-MTX)-based chemotherapy (early WBRT arm) did not prolong overall survival (OS) as compared to HD-MTX-based chemotherapy alone (no early WBRT arm) in primary CNS lymphoma (PCNSL) patients. To determine whether WBRT might lead to quality of life (QoL)-relevant late neurotoxicity, this trial prospectively monitored QoL. METHODS: QoL measurements were performed using the EORTC-QLQ-C30 and BN20 questionnaires and combined with repeated Mini Mental State Examinations (MMSE)...
April 22, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28432587/rituximab-methotrexate-procarbazine-vincristine-and-intensified-cytarabine-consolidation-for-primary-central-nervous-system-lymphoma-pcnsl-in-the-elderly-a-loc-network-study
#11
Caroline Houillier, Hervé Ghesquières, Cécile Chabrot, Carole Soussain, Guido Ahle, Sylvain Choquet, Emmanuelle Nicolas-Virelizier, Jacques-Olivier Bay, Jacques Vargaftig, Claude Gaultier, Valérie Touitou, Nadine Martin-Duverneuil, Nathalie Cassoux, Magali Le Garff-Tavernier, Myrto Costopoulos, Pierre Faurie, Khê Hoang-Xuan
Primary CNS lymphoma (PCNSL) is chemosensitive to high-dose methotrexate-based chemotherapy. However, responses in the elderly are short-lasting and outcome is poor. Given that radiotherapy and intensive chemotherapy expose elderly to severe toxicities, alternative consolidation approaches need to be evaluated. In this multicenter study, we retrospectively analyzed consecutive patients with newly-diagnosed PCNSL, aged >60, treated with a (R)-MPV-AAA regimen. The regimen consisted of three 28-day cycles of methotrexate (3...
April 21, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28427529/primary-central-nervous-system-lymphoma
#12
REVIEW
Giovanni Citterio, Michele Reni, Gemma Gatta, Andrés José Maria Ferreri
Primary CNS lymphomas (PCNSL) represent a subgroup of malignancies with specific characteristics, aggressive course, and unsatisfactory outcome in contrast with other lymphomas comparable for tumour burden and/or histological type. Despite a high chemo- and radiosensitivity, remissions are frequently shortlasting, mainly because the blood brain-barrier limits the access of many drugs to the CNS. Moreover, survivor patients are at high risk of developing severe treatment-related toxicity, mainly disabling neurotoxicity, raising the question of how to balance therapy intensification with side-effects control...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28427218/methotrexate-plus-idarubicin-improves-outcome-of-patients-with-primary-central-nervous-system-lymphoma
#13
Ni Fan, Lu Zhang, Xiaoping Xu, Bobin Chen, Chen Zhu, Pei Li, Zi Chen, Tianling Ding, Yan Ma, Yan Yuan, Zhiguang Lin
Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42...
March 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415725/stat3-positive-tumor-cells-contribute-to-vessels-neoformation-in-primary-central-nervous-system-lymphoma
#14
Simona Ruggieri, Roberto Tamma, Nicoletta Resta, Francesco Albano, Nicoletta Coccaro, Daria Loconte, Tiziana Annese, Mariella Errede, Giorgina Specchia, Rebecca Senetta, Paola Cassoni, Domenico Ribatti, Beatrice Nico
With the aim of elucidating the relationship between Stat3 expression and tumor vessels abnormalities in the PCNLs, in this study we evaluated Stat3 and pStat3 expression by Real-time PCR and by immunohistochemistry in biopsy sections from PCNSL patients. Correlations of the expression levels with the presence of aberrant vessels were analyzed by confocal laser microscopy analysis, using FVIII as endothelial cell marker, CD133 and nestin as cancer stem cell (CSC) marker, CD20 as tumor cell marker, and Stat3...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28369839/high-dose-chemotherapy-with-thiotepa-busulfan-and-cyclophosphamide-and-autologous-stem-cell-transplantation-for-patients-with-primary-central-nervous-system-lymphoma-in-first-complete-remission
#15
Zachariah DeFilipp, Shuli Li, Areej El-Jawahri, Philippe Armand, Lakshmi Nayak, Nancy Wang, Tracy T Batchelor, Yi-Bin Chen
BACKGROUND: High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) is a therapeutic option for patients with primary central nervous system lymphoma (PCNSL). To the authors' knowledge, data are limited regarding its use among patients in first complete remission (CR1) with the CNS-directed conditioning regimen of thiotepa, busulfan, and cyclophosphamide (TBC). METHODS: A retrospective analysis of patients with PCNSL in CR1 who underwent transplantation using a TBC-based conditioning regimen at 2 academic institutions was performed...
April 3, 2017: Cancer
https://www.readbyqxmd.com/read/28363832/primary-cns-lymphomas-of-the-brain-a-retrospective-analysis-in-a-single-institute
#16
Tzu-Kang Lin, Tu-Hsueh Yeh, Peng-Wei Hsu, Chih-Cheng Chuang, Po-Hsun Tu, Pin-Yuang Chen, Shih-Ming Jung, Kuo-Chen Wei, Yin-Cheng Huang
Primary CNS lymphomas (PCNSL) are relatively rare brain tumors. Their accurate diagnosis is mainly by surgical biopsy. In addition to surgical biopsy/decompression, treatment options include high dose methotrexate/chemotherapy and radiation therapy and stem cell therapy. Due to the rarity of this disease, guidelines for PCNSL diagnosis and treatment usually form from a large series of experiences. As a tertiary referral center, we retrospectively reviewed 79 patients during a 13-year period. All patients with PCNSL underwent surgical procedures/bone marrow biopsy procedures, and diagnoses were confirmed by hematologists/neuropathologists...
March 28, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28356247/pd-1-blockade-with-nivolumab-in-relapsed-refractory-primary-central-nervous-system-and-testicular-lymphoma
#17
Lakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G M Roemer, Bjoern Chapuy, Philippe Armand, Scott J Rodig, Margaret A Shipp
Primary central nervous system lymphoma (PCNSL) and primary testicular lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures. There are no standard of care treatment options for patients with relapsed and refractory PCNSL and PTL, and the overall prognosis is poor. PCNSLs and PTLs exhibit frequent 9p24.1 copy number alterations and infrequent translocations of 9p24.1 and associated increased expression of the programmed cell death protein 1 (PD-1) ligands PD-L1 and PD-L2...
March 29, 2017: Blood
https://www.readbyqxmd.com/read/28331101/immunotherapy-of-nivolumab-with-dendritic-cell-vaccination-is-effective-against-intractable-recurrent-primary-central-nervous-system-lymphoma-a-case-report
#18
Motomasa Furuse, Naosuke Nonoguchi, Naoki Omura, Mitsuaki Shirahata, Koichi Iwasaki, Toshio Inui, Toshihiko Kuroiwa, Hiroko Kuwabara, Shin-Ichi Miyatake
We report effective treatment with nivolumab of a patient with recurrent primary central nervous system lymphoma (PCNSL) after multiple therapies. A 41-year-old woman with a right parietal PCNSL underwent treatment with high-dose methotrexate and radiotherapy. After recurrence in the left frontal lobe, the patient received several chemotherapies, including methotrexate and rituximab, and underwent surgery. The tumor was refractory to these treatments, and the patient then underwent intensity-modulated radiotherapy (IMRT)...
April 15, 2017: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/28315229/primary-central-nervous-system-lymphoma-essential-points-in-diagnosis-and-management
#19
REVIEW
Semra Paydas
Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28301491/the-performance-of-mr-perfusion-weighted-imaging-for-the-differentiation-of-high-grade-glioma-from-primary-central-nervous-system-lymphoma-a-systematic-review-and-meta-analysis
#20
Weilin Xu, Qun Wang, Anwen Shao, Bainan Xu, Jianmin Zhang
It is always a great challenge to distinguish high-grade glioma (HGG) from primary central nervous system lymphoma (PCNSL). We conducted a meta-analysis to assess the performance of MR perfusion-weighted imaging (PWI) in differentiating HGG from PCNSL. The heterogeneity and threshold effect were evaluated, and the sensitivity (SEN), specificity (SPE) and areas under summary receiver operating characteristic curve (SROC) were calculated. Fourteen studies with a total of 598 participants were included in this meta-analysis...
2017: PloS One
keyword
keyword
59503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"